Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study

Santoro, Maria Mercedes; Armenia, Daniele; Teyssou, Elisa; Santos, JR; Charpentier, Charlotte; Lambert-Niclot, Sidonie; Antinori, Andrea; Katlama, Christine; Descamps, Diane; Perno, Carlo Federico; Cálvez, Vincent; Paredes, Roger; Ceccherini‐Silberstein, Francesca; Marcelin, Anne–Geneviève

doi:10.1016/j.jgar.2022.07.022

Cited by 20 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The low frequency of RAMs after virological failure with DTG + 3TC has been reported elsewhere. In a cohort of 712 individuals, Santoro et al detected only one poorly adherent patient, in whom M184V was selected after failure [13], and Galizzi et al reported selection of M184V in two out of 307 patients [10]. At virological failure, one patient in our cohort developed R263K, which confers intermediate resistance to all INSTIs [17].…”

Section: Discussionmentioning

confidence: 83%

“…The two regimen DTG + 3TC has demonstrated efficacy, good safety and tolerability, and a high barrier to resistance in treatment-naïve patients and has proved useful as a switching strategy in virologically suppressed patients [2,4,11]. Both clinical trials and real-world cohorts have confirmed this efficacy [7,[12][13][14]. However, long-term data remain scarce but critical when assessing the long-term durability and genetic barrier to resistance to DTG + 3TC.…”

Section: Discussionmentioning

confidence: 99%

“…The effect of a previous M184V mutation on the efficacy of DTG + 3TC remains controversial. In some analyses, M184V has been associated with virological failure in patients with a shorter duration of virological suppression [13,14]. However, its impact seems to be low in terms of virological failure.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Three‐year efficacy of switching to dolutegravir plus lamivudine: A real‐world study

et al. 2023

View full text Add to dashboard Cite

BackgroundDolutegravir (DTG) plus lamivudine (3TC) has proven highly efficacious as a switching strategy in virologically suppressed people with HIV (PWH). As this strategy was introduced relatively recently, real‐world, long‐term durability studies are lacking.MethodsWe performed a retrospective review of treatment‐experienced patients who started DTG + 3TC in a cohort of PWH. HIV‐RNA <50 copies/mL was analysed at 144 weeks in an intention‐to‐treat (ITT) analysis (missing = failure) and a per‐protocol (PP) analysis (patients with missing data or changes for reasons other than virological failure were excluded).ResultsThe study population comprised 358 PWH (19% women). Median age and time with HIV infection were 51.7 and 13.4 years, respectively. The median number of previous antiretroviral combinations was three. Previous virological failure was reported in 27.1% of patients, and the M184V resistance mutation was detected in 17 patients. At 144 weeks, the percentage of individuals with HIV‐RNA <50 copies/mL was 77.4% (277/358) in the ITT analysis and 95.5% (277/290) in the PP analysis. A total of 68 participants were excluded from the PP analysis (data missing, 25, discontinuation due to toxicity, 19; other, 16; death, 8). Two people with virological failure selected resistance‐associated mutations (M184V and M184V + R263K). HIV‐RNA remained undetectable in 17 patients with a previous history of the M184V mutation.ConclusionOur results confirm the real‐world, long‐term efficacy, tolerability and high genetic barrier of DTG + 3TC in treatment‐experienced PWH. Although scarce, mutations causing resistance to nucleosides and integrase can emerge.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Three‐year efficacy of switching to dolutegravir plus lamivudine: A real‐world study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Several cohorts have suggested that a historical M184V mutation does not affect the efficacy of DTG/3TC as maintenance treatment. In some analysis, a shorter duration of virological suppression or shorter time between M184V detection and switch to DTG/3TC were associated with a higher risk of virological failure [ 11 , 12 ]. However, a recent study analyzing with what to date is the largest cohort of persons receiving this treatment in this context did not find that the M184V mutation was associated to virological failure, including when the mutation was detected within 5 years of the switch [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

Buckley

Rial-Crestelo

Montejano

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…В рамках борьбы с ВИЧ-инфекцией активно проводятся клинические испытания новых антиретровирусных препаратов [3][4][5] и вакцин [6], изучаются побочные эффекты антиретровирусной терапии [7,8], исследуются пути оптимизации схем АРТ [9][10][11] и различные стратегии лечения [12,13], значительное внимание уделяется вопросу межлекарственных взаимодействий [14][15][16] и приверженности пациентов [17]. Каждое из таких исследований невозможно без систематизированного сбора и последующего многопланового анализа многочисленных клинико-эпидемиологических данных пациентов.…”

unclassified

RuSIDA: the online resource for the collection, storage and analysis of epidemiologicel, demographic and clinical laboratory data of patients

Кузнецова

Bobkov

Lebedev

et al. 2023

VIČ-infekc. immunosupr.

View full text Add to dashboard Cite

Objective on creating a universal tool with Russian user interface (UI) to systematically collect and store epidemiological-demographic and clinical-laboratory data of patients with the possibility of their structured export for subsequent multifaceted analysis.Materials and methods. When creating an online tool, the solutions of European colleagues used to conduct a multicenter study of EuroSIDA, including a list, algorithms for collecting, storing and exchanging data, were used as a model.Research and discussion. A Russian UI online resource RuSIDA has been developed, hosted on the website http://hivgen.org/, designed to fulfill the tasks above. The tool requires authorized access and has been successfully tested on data collection from HIV-infected patients at several AIDS centers in the Russian Federation.Conclusion. The developed online resource RuSIDA can be used to maintain medical electronic records, intralaboratory databases, as well as to conduct epidemiological monitoring of various nosologies and multicenter scientific studies.

show abstract

Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study

Cited by 20 publications

References 31 publications

Three‐year efficacy of switching to dolutegravir plus lamivudine: A real‐world study

Three‐year efficacy of switching to dolutegravir plus lamivudine: A real‐world study

Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

RuSIDA: the online resource for the collection, storage and analysis of epidemiologicel, demographic and clinical laboratory data of patients

Contact Info

Product

Resources

About